The use of recombinant factor VIII in the management of Hemophilia

Pier Mannuccio Mannucci, Alessandro Gringeri

Research output: Contribution to journalArticlepeer-review


Recombinant factor VIII is currently in the late stages of clinical trials. The available studies indicate that the product is safe and well-tolerated, and appears to be free of virus diseases such as HIV and hepatitis infections. Based on these early studies, recombinant coagulation factors appear to have enonnous promise and potential for transfusion medicine. The synthesis of large quantities of safe material may lead to the development of techniques for daily administration of factor VIII aimed at the prevention of joint and soft tissue bleedings. There is also the promise of decreased costs, as techniques for the efficient synthesis of recombinant proteins are refined further.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalLa Ricerca in Clinica e in Laboratorio
Issue number1
Publication statusPublished - Jan 1991


  • Factor VIII
  • Hemophilia
  • Infections
  • Plasma proteins
  • Recombinant factor VIII

ASJC Scopus subject areas

  • Clinical Biochemistry


Dive into the research topics of 'The use of recombinant factor VIII in the management of Hemophilia'. Together they form a unique fingerprint.

Cite this